Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
The current price of 8FW.F is €10.74 EUR — it has decreased by -1.83% in the past 24 hours. Watch Elektrotim stock price performance more closely on the chart.
What is Elektrotim stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Elektrotim stocks are traded under the ticker 8FW.F.
What is Elektrotim revenue for the last year?▼
Elektrotim revenue for the last year amounts to 0 EUR.
What is Elektrotim net income for the last year?▼
8FW.F net income for the last year is -70,387.32 EUR.
Does Elektrotim pay dividends?▼
Yes, 8FW.F dividends are paid annual. The last dividend per share was 0.59 EUR. As of today, Dividend Yield (FWD)% is 5.45%.